SEARCH

SEARCH BY CITATION

References

  • Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME (2005). Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 35: 10961103.
  • Bouteiller CL, Astruc R, Minty A, Ferrara P, Lupker JH (1995). Isolation of an IL-13-dependent subclone of the B9 cell line useful for the estimation of human IL-13 bioactivity. J Immunol Methods 181: 2936.
  • Bree A, Schlerman FJ, Wadanoli M, Tchistiakova L, Marquette K, Tan X-Y et al. (2007). IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 119: 12511257.
  • Chu HW, Trudeau JB, Balzar S, Wenzel S (2000). Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 106: 11151123.
  • Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J et al. (2010). A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. Am J Respir Crit Care Med 181: 788796.
  • Defrance T, Aubry JP, Rousset F, Vanbervliet B, Bonnefoy JY, Arai N et al. (1987). Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes. J Exp Med 165: 14591467.
  • Deshpande DA, Dogan S, Walseth TF, Miller SM, Amrani Y, Panettieri RA et al. (2004). Modulation of calcium signalling by IL-13 in human airway smooth muscle: role of CD38/cADPR pathway. Am J Respir Cell Mol Biol 31: 3642.
  • Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE et al. (2011). The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 183: 10071014.
  • Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM et al. (1998). Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282: 22612263.
  • Grunstein MM, Hakonarson H, Leiter J, Chen M, Whelen R, Grunstein JS et al. (2002). IL-13 dependent autocrine signalling mediates altered responsiveness of IgE-sensitised airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 282: L520L528.
  • GINA Guidelines (2010). GINA report, Global strategy for asthma management and prevention. http://www.ginasthma.org/pdf/GINA_report_2010.pdf .
  • Heinzmann A, Mao XQ, Akaiwa M, Kreomer RT, Gao PS, Ohshima K et al. (2000). Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 9: 549559.
  • Hershey GK (2003). IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 111: 677690.
  • Howard TD, Whittaker PA, Zaiman AL, Koppelman GH, Xu J, Hanley MT et al. (2001). Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol 25: 377384.
  • Howard TD, Koppelman GH, Xu J, Zheng SL, Postma DS, Meyers DA et al. (2002). Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 70: 230236.
  • Huang SK, Xiao HQ, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM et al. (1995). IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 155: 26882694.
  • Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R et al. (1997). Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99: 657665.
  • Jabara HH, Fu SM, Geha RS, Vercelli D (1990). CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 172: 18611864.
  • Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N et al. (2008). Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 325: 882892.
  • Kauppi P, Lindblad-Toh K, Sevon P, Toivonen HT, Rioux JD, Villapakkam A et al. (2001). A second-generation association study of the 5q31 cytokine gene cluster and the interleukin-4 receptor in asthma. Genomics 77: 3542.
  • Kaur D, Hollins F, Woodman L, Yang W, Monk P, May R et al. (2006). Mast cells express IL-13Rα1: IL-13 promotes human lung mast cell proliferation and FcεRI expression. Allergy 61: 10471053.
  • Komai-Koma M, McKay A, Thomson L, McSharry C, Chalmers GW, Liew FY et al. (2001). Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum. Clin Exp Allergy 31: 14411448.
  • Kotsimbos TC, Ernst P, Hamid QA (1996). Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Phys 108: 368373.
  • Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W (1996). Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 9: 899904.
  • Laporte JC, Moore PE, Baraldo S, Jouvin M, Church TL, Shwartzman IN et al. (2001). Direct effects of interleukin-13 on signalling pathways for physiological responses in cultured human airway smooth muscle cells. Am J Respir Crit Care Med 164: 141148.
  • Liu X, Nickel R, Beyer K, Wahn U, Ehrlich E, Freidhoff LR et al. (2000). An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). J Allergy Clin Immunol 106: 167170.
  • McKenzie AN, Li X, Largaespada DA, Sato A, Kaneda A, Zurawski SM et al. (1993). Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 150: 54365444.
  • McMillan SJ, Bishop B, Townsend MJ, McKenzie AN, Lloyd CM (2002). The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med 195: 5157.
  • Martin PL, Fisher D, Glass W, O'Neil K, Das A, Martin EC et al. (2008). Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma. Int J Toxicol 27: 351358.
  • Matsukura S, Stellato C, Georas SN, Casolaro V, Plitt JR, Miura K et al. (2001). Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 24: 755761.
  • Moore PE, Church TL, Chism DD, Panettieri RA Jr, Shore SA (2002). IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. Am J Physiol Lung Cell Mol Physiol 282: L847L853.
  • Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME (2008). Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A 105: 72407245.
  • Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ et al. (1997). Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 155: 845851.
  • Obase Y, Shimoda T, Mitsuta K, Matsuo N, Matsuse H, Kohno S (2001). Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. Ann Allergy Asthma Immunol 86: 304310.
  • Pène J, Rousset F, Brière F, Chrétien I, Bonnefoy JY, Spits H et al. (1988). IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A 85: 68806884.
  • Peters SP, Ferguson G, Deniz Y, Reisner C (2006). Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 100: 11391151.
  • van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO et al. (1999). An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1: 6165.
  • Punnonen J, de Vries JE (1994). IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. J Immunol 152: 10941102.
  • Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G et al. (1993). Interleukin 13 induces interleukin -4 independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A 90: 37303734.
  • Sabroe I, Hartnell A, Jopling LA, Bel S, Ponath PD, Pease JE et al. (1999). Differential regulation of eosinophil chemokine signalling via CCR3 and non-CCR3 pathways. J Immunol 162: 29462955.
  • Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R et al. (2008). Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 121: 685691.
  • Sironi M, Sciacca FL, Matteucci C, Conni M, Vecchi A, Bernasconi S et al. (1994). Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood 84: 19131921.
  • Skinnider BF, Kapp U, Mak TW (2001). Interleukin 13: a growth factor in Hodgkin lymphoma. Int Arch Allergy Immunol 126: 267276.
  • Tamura K, Suzuki M, Arakawa H, Tokuyama K, Morikawa A (2003). Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int Arch Allergy Immunol 131: 3338.
  • Terada N, Hamano N, Nomura T, Numata T, Hirai K, Nakajima T et al. (2000). Interleukin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy 30: 348355.
  • Thom G, Cockroft AC, Buchanan AG, Candotti CJ, Cohen ES, Lowne D et al. (2006). Probing a protein-protein interaction by in vitro evolution. Proc Natl Acad Sci U S A 103: 76197624.
  • Tliba O, Deshpande D, Chen H, van Beisien C, Kannan M, Panettieri RA et al. (2003). IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 140: 11591162.
  • Turner CR, Andresen CJ, Smith WB, Watson JW (1996). Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. Inflamm Res 45: 239245.
  • Vladich FD, Brazille SM, Stern D, Peck ML, Ghittoni R, Vercelli D (2005). IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 115: 747754.
  • Wakeland E, Morel L, Achey K, Yui M, Longmate J (1997). Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 10: 472477.
  • Webb DC, McKenzie ANJ, Koskinen AML, Yang M, Mattes J, Foster PS (2000). Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 165: 108113.
  • Wenzel SE, Trudeau JB, Barnes S, Zhou X, Cundall M, Wescott J et al. (2002). TGF-β and IL-13 synergistivally increase eotaxin-1 production in human airway fibroblasts. J Immunol 169: 46134619.
  • Wenzel S, Wilbraham D, Fuller R, Burmeister Getz E, Longphre M (2007). Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370: 14221431.
  • Wenzel SE, Ind PW, Otulana BA, Bleecker ER, Kuna P, Yen YP (2010). Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. P3980, 714s, European Respiratory Society 2010 Meeting. http://www.ersnet.org/learning_resources_player/abstract_print_10/main_frameset.htm .
  • Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL et al. (1998). Interleukin-13: central mediator of allergic asthma. Science 282: 22582261.
  • Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J et al. (1999). Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103: 779788.